Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Episurf Medical AB (EPIS-B.ST)
Stockholm, AB, SE
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient’s distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.62% | +6.30% | +161.30% | +348.24% | +472.32% | +298.55% | +116.64% | -80.59% | -93.19% | -96.94% | -96.47% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+3.9% Q1'26: -25.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+60.7% ★ Q1'26: +46.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-5.9% Q1'26: +376.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-424.4% Q1'26: -1,013.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-121.4% Q1'26: -22.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+99.4% Q1'26: +201.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.14× Q1'26: -0.04× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.02M
est: 2.54M (-60.0%)
|
2.41M
est: 3.73M (-35.4%)
|
2.49M
est: 2.67M (-6.8%)
|
4.00M
est: 4.67M (-14.3%)
|
4.90M
est: 5.89M (-16.7%)
|
5.00M
est: 5.99M (-16.5%)
|
6.50M
est: 7.43M (-12.5%)
|
6.60M
est: 7.66M (-13.8%)
|
10.30M
est: 11.70M (-12.0%)
|
13.00M
est: 13.00M (+0.0%)
|
13.50M
est: 13.60M (-0.7%)
|
25.40M
25.40M – 25.40M
+86.8% YoY
|
53.80M
53.80M – 53.80M
+111.8% YoY
|
108.60M
108.60M – 108.60M
+101.9% YoY
|
| EBITDA |
-41.74M
est: -2.54M (-1,544.4%)
|
-57.61M
est: -3.73M (-1,446.5%)
|
-56.91M
est: -2.67M (-2,029.2%)
|
-52.40M
est: -4.67M (-1,023.2%)
|
-64.30M
est: -5.89M (-992.6%)
|
-58.00M
est: -5.99M (-868.1%)
|
-63.80M
est: -7.43M (-758.9%)
|
-71.40M
est: -7.66M (-832.6%)
|
-87.70M
est: -11.70M (-649.6%)
|
-69.00M
est: -13.00M (-430.8%)
|
-49.20M
est: -13.60M (-261.8%)
|
-25.40M
-25.40M – -25.40M
-86.8% YoY
|
-53.80M
-53.80M – -53.80M
-111.8% YoY
|
-108.60M
-108.60M – -108.60M
-101.9% YoY
|
| EBIT |
-43.97M
est: -2.54M (-1,632.5%)
|
-61.66M
est: -3.73M (-1,555.4%)
|
-61.10M
est: -2.67M (-2,186.0%)
|
-57.20M
est: -4.67M (-1,126.0%)
|
-69.00M
est: -5.89M (-1,072.5%)
|
-63.20M
est: -5.99M (-954.9%)
|
-69.00M
est: -7.43M (-828.9%)
|
-76.50M
est: -7.66M (-899.2%)
|
-93.70M
est: -11.70M (-700.9%)
|
-75.00M
est: -13.00M (-476.9%)
|
-57.30M
est: -13.60M (-321.3%)
|
-25.40M
-25.40M – -25.40M
-86.8% YoY
|
-53.80M
-53.80M – -53.80M
-111.8% YoY
|
-108.60M
-108.60M – -108.60M
-101.9% YoY
|
| Net Income |
-43.97M
est: -945.62M (+95.3%)
|
-61.67M
est: -532.32M (+88.4%)
|
-61.09M
est: -372.88M (+83.6%)
|
-57.80M
est: -375.89M (+84.6%)
|
-70.60M
est: -211.48M (+66.6%)
|
-64.60M
est: -103.64M (+37.7%)
|
-69.50M
est: -67.67M (-2.7%)
|
-77.30M
est: -70.92M (-9.0%)
|
-94.80M
est: -301.35M (+68.5%)
|
-76.00M
est: -77.88M (+2.4%)
|
-58.20M
est: -50.14M (-16.1%)
|
-98.65M
-98.65M – -98.65M
-96.7% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
325.0K
est: -748.4K (+143.4%)
|
485.4K
est: -1.10M (+144.2%)
|
33.30M
est: -788.1K (+4,325.4%)
|
-4.30M
est: -1.38M (-212.6%)
|
1.10M
est: -1.74M (+163.4%)
|
1.20M
est: -1.77M (+167.9%)
|
-4.40M
est: -2.19M (-100.9%)
|
-9.30M
est: -2.26M (-312.0%)
|
-5.60M
est: -2.12M (-163.9%)
|
11.90M
est: -2.36M (+604.7%)
|
10.90M
est: -2.47M (+541.9%)
|
-4.61M
-4.61M – -4.61M
-86.8% YoY
|
-9.76M
-9.76M – -9.76M
-111.8% YoY
|
-19.70M
-19.70M – -19.70M
-101.9% YoY
|
| EPS |
-1.09
est: -1.91 (+42.9%)
|
-1.32
est: -1.08 (-22.9%)
|
-0.89
est: -0.75 (-18.5%)
|
-0.90
est: -0.76 (-18.4%)
|
-0.55
est: -0.43 (-29.2%)
|
-0.21
est: -0.21 (-0.9%)
|
-0.16
est: -0.14 (-19.6%)
|
-0.15
est: -0.14 (-4.6%)
|
-0.20
est: -0.31 (+33.1%)
|
-0.15
est: -0.08 (-90.0%)
|
-0.06
est: -0.05 (-16.1%)
|
-0.10
-0.10 – -0.10
-96.7% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leif Ryd | Consultant, Member of Clinical Advisory Board & Director | 500.0K | — |
| Katarina Flodström | Deputy CEO & Head of Medical Technology Operations | 400.0K | female |
| Jens Andersson | CEO & Director | — | male |
| Fredrik Zetterberg | Marketing Director | — | male |
| Patrick Jamnik | President of Episurf Medical Inc | — | male |
| Sanja Batljan | Chief Financial Officer | — | female |
| Ylva Bonde | Head of Quality & Regulatory Affairs | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EPIS-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
